Abstract
AbstractFC-12738, a retro-inverso pentapeptide developed by Neurodegenerative Disease Research, Inc., is currently under investigation for treating neuroinflammation associated with amyotrophic lateral sclerosis (ALS). This study aimed to evaluate the pharmacokinetic properties of FC-12738, including absorption, distribution, metabolism, excretion, and drug-drug interactions. Pharmacokinetics were assessed in Sprague-Dawley rats and beagle dogs following intravenous and subcutaneous administration. Our findings suggest that FC-12738 demonstrates many favorable pharmacokinetic properties, although further optimization may be required to improve CNS penetrance.
Publisher
Cold Spring Harbor Laboratory
Reference14 articles.
1. The in vivo immunomodulatory and synergistic antitumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2;Cancer Lett. Ireland,2013
2. A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science;United States,1979
3. Thymopoietin to thymopentin: experimental studies;Surv Immunol Res. Switzerland,1985
4. The amino acid sequence of thymopoietin II;Cell. United States,1975
5. Three distinct human thymopoietins are derived from alternatively spliced mRNAs. Proc Natl Acad Sci U S A;United States,1994